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Abstract
Background: A meta-analysis of observational studies comparing differences in outcomes between restrictive blood
transfusion (RBT) and liberal blood transfusion (LBT) in patients with acute myocardial infarction (AMI) reported that
LBT is associated with higher all-cause mortality. Few randomized clinical trials (RCTs) have compared RBT to LBT in
patients with AMI and anemia, but no meta-analysis of RCTs was performed to date.
Aim: To assess the clinical effect of RBT compared to LBT in patients with AMI and anemia regarding was all-cause
mortality, recurrent MI, revascularization, and heart failure exacerbation.
Methods: The electronic databases Ovid MEDLINE, EMBASE, Cochrane Central, Scopus, and Google Scholar, were
systematically searched to identify eligible studies published before June 19th, 2021. RCTs that assessed the effect of
RBT compared to LBT were included. The primary endpoint was all-cause mortality. Secondary endpoints included
recurrent MI, revascularization, and heart failure exacerbation.
Results: Three RCTs with 821 patients were included (421 received RBT, and 400 received LBT). The mean age was
75.9 ± 6.1 years, and 56% were male. Our meta-analysis showed that RBT was not associated with reduced all-cause
mortality (RR ¼ 1.61; 95% CI ¼ 0.38e6.96, p ¼ 0.52), recurrent MI (RR ¼ 0.98; 95% CI ¼ 0.48e1.96, p ¼ 0.94), revascularization (RR ¼ 1.18; 95% CI ¼ 0.26e5.44, p ¼ 0.83) and heart failure exacerbation (RR ¼ 0.86; 95% CI ¼ 0.23e3.22,
p ¼ 0.82) when compared to LBT.
Conclusion: RBT was not associated with reduced all-cause mortality, recurrence of MI, need for revascularization, or
heart failure exacerbation in patients with AMI and anemia compared to LBT. A larger RCT is required to conﬁrm the
above ﬁndings.
Keywords: Blood transfusion, Liberal, Restrictive, Myocardial infarction, Acute coronary syndrome, Anemia, Systematic
review, meta-Analysis

1. Introduction

B

lood transfusion is indicated in patients with severe anemia to improve tissue oxygenation,
symptoms, and possibly clinical outcomes.1 Anemia
in patients with acute myocardial infarction (AMI) is a
strong predictor of cardiovascular morbidity, mortality, and ischemic events.2,3 Current guideline suggests
that restrictive blood transfusion (RBT) (transfusion at
hemoglobin [Hb] level of <7 g/dL) is as effective as

liberal blood transfusion (LBT) (transfusion at Hb of
<10 g/dL) with the exception of patient with MI.1
There are no clear guidelines in this patient population to date. The result of a recent randomized clinical
trial (RCT) favored RBT over LBT in this population.4
Data from a meta-analysis of observational studies
also favored RBT and reported that LBT is associated
with higher all-cause mortality.5
Our meta-analysis aims to analyze the most recent
data from randomized clinical trials to update the
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Fig. 1. The ﬂow diagram of the study identiﬁcation, inclusion, and exclusion process.

current evidence on whether RBT has clinical beneﬁts regarding all-cause mortality, recurrent
myocardial infarction (MI), revascularization, and
heart failure exacerbation in patients with AMI and
anemia when compared to LBT.

2. Methods

“Liberal” OR “Restrictive”) AND (“Myocardial
infarction” OR “Coronary” OR “Angina”) for literature
published up until June 19th, 2021. In addition, we
included additional articles found in the review of
bibliographies or suggested by co-authors based on
their relevance to the selected search terms.
2.2. Study selection and eligibility criteria

2.1. Data sources and search strategy
This systematic review was conducted according to
The Preferred Reporting for Systematic Review and
Meta-Analysis (PRISMA) as recommended by
Cochrane Collaboration.6 A systematic literature review using MEDLINE, EMBASE, Cochrane Central,
Scopus, and Google Scholar was performed using the
terms (“Transfusion” OR “Blood transfusion” OR

Search results were saved in EndNote and transferred to Covidence.7 Two reviewers (BM and EK)
independently performed the title and abstract
screening. Conﬂicts were resolved through a third
author (BA). The selected articles were further
screened using the following inclusion criteria: RCT;
study population involving patients with MI; outcomes including all-cause mortality, recurrent MI,
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Table 1. Summary of the included studies.
Country/Length of Study

Study Design

Total Participants
(LBT/RBT)

Intervention

Reported outcomes

Cooper et al.
2011 [11]

USA
May 2003 to October 2009

Prospective, multicenter
parallel group randomized
pilot trial

45 (21/24)

In-hospital
death,
recurrent
ischemia/MI, new or worsening
heart failure, CCU and hospital
LOS

Carson et al.
2013 [10]

USA
March 2010 to May 2012

Multicenter, randomized
pilot trial

110 (55/55)

Ducrocq et al.
2021 [4]

France and Spain/March 2016
to September 2019

Open label, noninferiority,
randomized trial

668 (324/342)

Liberal Transfusion group: transfuse
if Hct <30%, goal to maintain between 30 and 33%.
Restrictive transfusion group transfused when Hct <24%, the goal between 24 and 27%. If Hct was >5%
below targets, 2 U of PRBCs were
given prior to reassessment
liberal transfusion strategy received
1 U of blood to target Hb  10 g/dL.
Restrictive
transfusion
strategy
received blood for symptoms from
anemia or for hemoglobin <8 g/dL if
symptomatic, no lower threshold for
infusion in the restrictive group.
Blood was only given to raise Hb
above 8 g/dL or alleviate symptoms
and signs.
Liberal strategy group, transfusion
for a Hb level less than or equal to
10 g/dL, with post-transfusion Hb
level of at least 11 g/dL.
Restrictive strategy group, no transfusion was to be performed unless
Hb level decreased to less than or
equal to 8 g/dL, with post-transfusion Hb target range of 8e10 g/dL

LBT: Liberal blood transfusion; RBT: Restrictive blood transfusion; Hct: Hematocrit; U: Units; PRBCs: Packed red blood cells.

Recurrent MI/Ischemia, Death,
unscheduled
re-admission,
adverse events (stroke, PE, DVT,
CHF)

Major adverse cardiovascular
events,
death,
recurrent
ischemia/MI, adverse events
(AKI, stroke, CHF, infection)
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Study

revascularization; English written text; Full text. We
excluded the observational studies, studies that
included non-cardiac patients, and non-full text articles. Conﬂicts were resolved through the third
author (BA).
2.3. Data extraction
Data from included studies were extracted independently by two reviewers (BM, EK). The
consensus was reached in case of any inconsistency
by the third author (BA). The data extracted for
qualitative synthesis included location, year of
study, study design, sample size, population age (in
years), all-cause mortality, recurrent MI, revascularization, heart failure exacerbation. The data were
entered in Microsoft Excel by (BM, EK) and
reviewed by a third author (BA). Any discrepancy
was resolved by discussion between authors.
2.4. Risk of bias assessment
We used The Cochrane Collaboration tool to
perform quality assessment and assess the risk of
bias in the included clinical trials for random
sequence generation, allocation concealment,
blinding of participants and health care personnel,
blinding of outcome assessment, incomplete
outcome data, evidence of selective reporting, and
other biases.8 The risk of bias assessment of the
studies was categorized into low risk, high risk, or
unclear risk of bias.
2.5. Outcomes of interest
The primary outcome was all-cause mortality.
Secondary outcomes included recurrent MI, revascularization, and heart failure exacerbation.
2.6. Statistical analysis
We calculated the pooled Relative Risk (RRs), 95%
conﬁdence intervals (CIs) for dichotomous data. We
used a random-effects model for the analysis. We
assessed heterogeneity using I2 statistics. I2 more
than 50% indicated a high level of heterogeneity. All
analyses were performed using RevMan manager
v5.4 software.9

3. Results

43

citations were selected as potentially relevant. The
titles and the abstracts were screened, and 37 fulltext articles were selected for further review. Thirtyfour articles were excluded; 21 did not include the
targeted population, 9 were not randomized
controlled trials (RCTs), two failed to report the
intervention of interest, one failed to report the
deﬁned endpoints, and one is an ongoing trial.
Finally, three articles were included in our systematic review and meta-analysis (Fig. 1).
3.2. Characteristics of included studies
Table 1 outlines the summaries of each study
included. Two RCTs used hemoglobin (Hb) levels of
10 g/dL for LBT and 8 g/dL for RBT.4,10 The third RCTs
used a hematocrit value of 30% for LBT and 24% for
RBT.11 Three randomized clinical trials included 821
patients (421 received RBT, and 400 received LBT). The
mean age of participants was 75.9 ± 6.1, and 56% were
males. Co-morbidities in patients at enrollment
included hypertension, hyperlipidemia, and diabetes
mellitus in 79%, 60%, and 52%, respectively. The patients' demographics and baseline characteristics are
presented in Table 2.
3.3. Assessments of bias, study quality, and
heterogeneity
Most of the studies included in this systematic
review were RCTs that provided high-quality evidence. All RCTs had a low risk for selection, and
attrition biases. All RCTs had a high risk of performance bias as blinding of participants and personal
was not applicable. Detection bias was unclear in
two RCTs and low risk of bias in the third one. The
detailed assessment of the risk of bias is summarized in Fig. 2.
3.3.1. Primary endpoints
No signiﬁcant difference was found between RBT
and LBT groups regarding all-cause mortality:
(RR ¼ 1.61; 95% CI ¼ 0.38e6.96, p ¼ 0.52) (Fig. 3).
3.3.2. Secondary endpoints
There were no signiﬁcant difference with regards
to recurrent (MI) (RR ¼ 0.98; 95% CI ¼ 0.48e1.96,
p ¼ 0.94), revascularization (RR ¼ 1.18; 95%
CI ¼ 0.26e5.44, p ¼ 0.83), and heart failure exacerbation (RR ¼ 0.86; 95% CI ¼ 0.23e3.22, p ¼ 0.82) (Fig. 3).

3.1. Study identiﬁcation and selection

4. Discussion

We identiﬁed 496 relevant citations through the
literature search. After removing the duplicates, 277

In this updated meta-analysis of RCTs, which
included 821 participants comparing RBT to LBT in

REVIEW ARTICLE

JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES 2022;12:40e47

44

JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES 2022;12:40e47

REVIEW ARTICLE

Table 2. The patient demographics and baseline characteristics.
Study

Subgroup

Age (years),
Mean ± SD

Cooper et al.
2011
Carson et al.
2013
Ducrocq et al.
2021

Liberal (n ¼ 21)
Restrictive (n ¼ 24)
Liberal (n ¼ 55)
Restrictive (n ¼ 55)
Liberal (n ¼ 324)
Restrictive (n ¼ 342)

76.4
70.3
67.3
74.3
78
76

±
±
±
±

13.5
14.3
13.6
11.1

BMI (kg/m2),
Mean ± SD

Male %

Female %

White %

Smoker %

N/A
N/A
29.1 ±
28.3 ±
26.9 ±
26.4 ±

48
54
50.9
49.1
56.8
58.8

52
46
49.1
50.9
43.2
41.2

76
61
70.9
74.6
82.6
88.7

10
33
12.7
14.6
37.9 former/14.0 current
36.7 former/16.1 current

7.2
6.1
5.3
5.0

BMI: Body mass index; HTN: Hypertension; HLP: Hyperlipidemia; DM: diabetes mellitus; ESRD: end stage renal disease; CHF: congestive heart
failure; H/O: History of; CABG: Coronary artery bypass graft; PCI: percutaneous intervention.

Fig. 2. Risk of bias assessment. A: Risk of bias summary: review authors' judgments about each risk of bias item for each included study. The items are
scored (þ) low risk; () high risk; (?) unclear risk of bias. B Risk of bias graph: review authors' judgments about each risk of bias item presented as
percentages across all included studies.

HTN
(%)

HLD
(%)

DM
(%)

Anemia
(%)

ESRD/Renal
Failure/insufﬁciency/
Dialysis (%)

91
75
85.5
81.8
79
79.5

76
63
69.1
65.5
62
55.3

81
54
61.8
52.7
48.8
51.5

N/A
N/A
41.8
40
19.1
17.8

19
17
34.6
30.9
9.3
7.3

patients with AMI and anemia, there was no difference between RBT and LBT with regards to allcause mortality, recurrent MI, revascularization, and
heart failure exacerbation. These results are
considered reassuring for providers in a time of
signiﬁcant nationwide blood product shortages.
A previous meta-analysis by Chatterjee et al.
assessed the beneﬁts of blood transfusion in patients with AMI and reported that LBT was associated with higher all-cause mortality (RR ¼ 2.91;
95% CI ¼ 2.46e3.44; P < 0.001).5 They included

CHF
(%)

H/O CABG
(%)

H/O PCI
(%)

25.5
34.6
11.7
12.9

29
17
29.1
32.7
13
12.9

24
25
43.6
40
34.3
33.3

nine observational studies and only one RCT with
diverse study designs and patients' characteristics,
leading to heterogeneity in the outcome and
limiting their applicability. Our meta-analysis only
included RCTs and demonstrated no difference
between RBT and LBT regarding all-cause mortality,
recurrent MI, revascularization, and heart failure
exacerbation.
Holst et al. conducted a similar meta-analysis
reviewing the beneﬁts and harms of RBT and LBT.12
They reported that there was no difference in all-

Fig. 3. A forest plot compared the all-cause mortality, recurrent myocardial infarction (MI), revascularization, heart failure exacerbation between
restrictive and liberal blood transfusion. df, degrees of freedom; MH, Mantel-Haenszel; CI, conﬁdence interval; SD, standard deviation.
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cause mortality (RR ¼ 0.95; 95% CI ¼ 0.81 to 1.11;
I2 ¼ 27%), overall morbidity (RR ¼ 1.06 (0.93e1.21);
I2 ¼ 58%), and recurrent MI (RR ¼ 1.05 (0.82e1.36);
I2 ¼ 6%). They included surgical and medical patients, adults or children, in different settings,
including trauma, critical care, and perioperative
settings. All of these factors will change the effect
size. We only included the RCTs that included adult
patients with ACS, and we also included the recent
study by Ducrocq et al. 2021.4
Ducrocq et al., 2021 included 668 patients
comparing RBT versus LBT in patients with AMI
and Anemia.4 The primary outcomes were - allcause mortality, reinfarction, stroke, and emergency
revascularization prompted by ischemia. They reported the primary outcome in 11.0% of the patients
in the RBT group versus 14.0% in the LBT group
(hazard ratio 0.77, 95% conﬁdence interval
0.50e1.18, p < 0.05 for noninferiority, p ¼ 0.22 for
superiority), all-cause mortality: 5.6% vs. 7.7%
(p > 0.05), recurrent MI: 2.1% vs. 3.1%, emergency
revascularization: 1.5% vs. 1.9%, Acute heart failure
3.2% vs. 1.9%. They concluded that RBT was noninferior to the LBT. The study did not have sufﬁcient
power to evaluate the superiority of either strategy.
On the other hand, Deharo et al., 2020 compared
the beneﬁts and risk of blood transfusion versus no
transfusion in patients with AMI and anemia.13
They included 12,547 patients, and blood transfusion was used in 489 (3.9%) patients. They reported that the patients who received transfusion
had a higher rate of death or MI (29.9% vs. 8.1%,
p < 0.01), suggesting the potential risk of harm in
patients who received a blood transfusion. The RCT
by Deharo et al., 2020 is different from the included
RCTs in our meta-analysis as Deharo, and his
colleague compared blood transfusion to no transfusion.13 The indication for transfusion was not
prespeciﬁed because this study is post hoc analysis
from anticoagulation with otamixaban and ischemic
events in non-ST segment elevation acute coronary
syndromes trial (TAO randomized clinical trial).14
This ﬁnding should not be applied clinically as it
was interpreted as a generated hypothesis only. Our
study included RCTs that compared RBT versus
LBT, and all the outcomes were prespeciﬁed in the
protocols prior to commencing each respective trial.
Our study had several strengths but also some
limitations. Firstly, the reported outcomes were
derived from a small number of RCTs, and as a
result, more RCTs are needed before making clinical recommendations based on these studies. A
larger ongoing RCT (Myocardial Ischemia and
Transfusion; MINT trial; NCT02981407) will include
3500 participants and has the same clinical design.

The primary outcome will be a 30-day composite of
all-cause mortality or nonfatal MI. Secondly, our
results have wide conﬁdence intervals due to
limited trial data that could be included. Finally, the
assessment of publication bias using the funnel plot
is not reliable for less than ten included studies, as
reported by Egger et al. Therefore, in the present
meta-analysis, we could not examine the possibility
of publication bias.15

5. Conclusions
The result of our meta-analysis suggests that RBT
compared with LBT is not associated with reduced
all-cause mortality, rates of recurrent MI, revascularization, or heart failure exacerbations when
compared to liberal blood transfusion in patients
with AMI and anemia. Our results are believed to be
reassuring to healthcare providers during times of
signiﬁcant nationwide shortage of blood products. However, Larger RCTs are needed before
recommending the appropriate transfusion strategy
in this patient population.
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